Literature DB >> 21953363

Effect of raloxifene (a Selective Estrogen Receptor Modulator (SERM)) as coadjuvant to antidepressant treatment: a case report.

Judith Usall1, Marta Coromina, Susana Araya, Susana Ochoa.   

Abstract

We report a case of a woman with a depressive disorder with partial response to antidepressant treatment. Raloxifene, a Selective Estrogen Receptor Modulator (SERM) was added to the treatment, the patient achieving complete remission of her depressive symptoms. The interest of our case lies in the fact that it exemplifies the relationship between depressive disorders and hormonal changes during menopause. Furthermore, raloxifene may become a novel therapeutic option in some postmenopausal women who do not respond or only partially respond to SSRIs, especially in those with a history of depressive disorders related to menopause.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21953363

Source DB:  PubMed          Journal:  Actas Esp Psiquiatr        ISSN: 1139-9287            Impact factor:   1.196


  2 in total

1.  Chaihu-Shugan-San administration ameliorates perimenopausal anxiety and depression in rats.

Authors:  Shujiao Chen; Tetsuya Asakawa; Shanshan Ding; Linghong Liao; Lingyuan Zhang; Jianying Shen; Jie Yu; Kenji Sugiyama; Hiroki Namba; Candong Li
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

2.  Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial.

Authors:  Gilda Kianimehr; Farzad Fatehi; Sara Hashempoor; Mohammad-Reza Khodaei-Ardakani; Farzin Rezaei; Ali Nazari; Ladan Kashani; Shahin Akhondzadeh
Journal:  Daru       Date:  2014-07-10       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.